Novavax cuts 2024 revenue forecast, shrinks European presence
Adds executive comments in paragraphs 3 and 5
By Leroy Leo
Aug 8 (Reuters) -Novavax NVAX.O on Thursday trimmed its annual revenue forecast again and said it would pare back its presence in Europe through the rest of the year, ahead of handing over the rights to sell its COVID-19 vaccine to partner Sanofi SASY.PA in 2025.
The company's vaccine had failed to make a significant dent in the market share of early COVID-vaccine entrants such as Pfizer/BioNTech PFE.N, 22UAy.DE and Moderna MRNA.O, and last year raised doubts about its ability to remain in business.
"We are concentrating our commercial efforts for the remainder of the year on our largest market, the U.S.," Chief Operating Officer John Trizzino said on a post-earnings call.
The company would reduce its sales infrastructure in Europe and focus on select markets such as Germany, Italy and Poland.
Novavax expects overall demand for COVID vaccines in the U.S. to remain similar to last year, but anticipates its own performance to be better, Trizzino said.
The company has sought authorization for its fall-season COVID shot targeting the JN.1 strain from the U.S. and European regulators.
Its shares rose 5% on Thursday. The stock has plunged more than 95% from the high hit in 2021 during the peak of the pandemic.
In May, Novavax signed a licensing deal worth at least $1.2 billion with Sanofi for its COVID vaccine.
The deal provided the U.S. biotech firm with much needed liquidity while boosting the French drugmaker's plans to co-develop a combination of its influenza and COVID vaccine.
Novavax, which missed second-quarter revenue and profit estimates, cut its full-year forecast range for total revenue to $700 million to $800 million, from between $970 million and $1.17 billion.
Last week, Moderna also cut its 2024 revenue forecast, partly due to low COVID sales in the EU.
Novavax now expects $275 million to $375 million in product sales for the year, compared with its earlier forecast of between $400 million and $600 million, which also included royalties and other revenue.
Reporting by Leroy Leo in Bengaluru and Michael Erman in New York; Editing by Maju Samuel
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
